POINT Biopharma Global Inc.

POINT Biopharma Global Inc., listed under the ticker RACA, is a clinical-stage radiopharmaceutical company focused on developing and commercializing radioligand therapies for oncology indications. The company entered the public markets through a SPAC merger in 2021, operating within the healthcare and precision medicine sector. On December 27, 2023, the company filed an 8-K current report with the SEC under accession number 0001193125-23-303512, representing a formal disclosure submission during a notable period of corporate activity in the radiopharmaceuticals space. POINT Biopharma has pursued a pipeline centered on targeted cancer treatment using radioactive isotopes. For complete filing histories, sponsor profiles, and deal analytics on POINT Biopharma and thousands of other SPAC transactions, sign up for full data access at SpacDesk.